Sanara MedTech Inc. (SMTI)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net revenue | 25,830,834 | 23,434,096 | 21,671,599 | 20,158,823 |
| Cost of goods sold | 1,937,282 | 1,834,967 | 1,991,987 | 2,008,686 |
| Gross profit | 23,893,552 | 21,599,129 | 19,679,612 | 18,150,137 |
| Selling, general and administrative | 21,553,194 | 21,440,610 | 18,993,255 | 18,957,608 |
| Research and development | 1,257,475 | 1,114,138 | 1,359,530 | 985,651 |
| Depreciation and amortization | 1,114,231 | 1,124,410 | 1,103,854 | 1,105,507 |
| Change in fair value of earnout liabilities | - | - | -147,000 | 13,773 |
| Total operating expenses | 23,924,900 | 23,679,158 | 21,603,639 | 21,034,993 |
| Operating loss | -31,348 | -2,080,029 | -1,924,027 | -2,884,856 |
| Interest income | - | 3,672 | - | - |
| Interest expense | 1,791,568 | 1,317,092 | 927,577 | 644,346 |
| Share of losses from equity method investments | -195,482 | -143,608 | -31,448 | - |
| Gain on disposal of property and equipment | - | 9,674 | - | - |
| Total other income (expense) | -1,987,050 | -1,447,354 | -959,025 | -644,346 |
| Net loss | -2,018,398 | -3,527,383 | -2,883,052 | -3,529,202 |
| Less net loss attributable to noncontrolling interest | -4,036 | -206 | -25,284 | -25,188 |
| Net loss attributable to sanara medtech shareholders | -2,014,362 | -3,527,177 | -2,857,768 | -3,504,014 |
| Net loss per share of common stock, basic | -0.23 | -0.41 | -0.34 | -0.41 |
| Net loss per share of common stock, diluted | -0.23 | -0.41 | -0.34 | -0.41 |
| Weighted average number of common shares outstanding, basic | 8,612,986 | 8,570,104 | 8,517,381 | 8,468,835 |
| Weighted average number of common shares outstanding, diluted | 8,612,986 | 8,570,104 | 8,517,381 | 8,468,835 |